Characterizing the landscape of peritoneal exosomal microRNAs in patients with ovarian cancer by high-throughput sequencing.
epithelial ovarian cancer
miR-149-3p
miR-222-5p
microRNA
next-generation sequencing
Journal
Oncology letters
ISSN: 1792-1074
Titre abrégé: Oncol Lett
Pays: Greece
ID NLM: 101531236
Informations de publication
Date de publication:
Jan 2019
Jan 2019
Historique:
received:
28
11
2017
accepted:
13
06
2018
entrez:
19
1
2019
pubmed:
19
1
2019
medline:
19
1
2019
Statut:
ppublish
Résumé
In the present study, differentially expressed microRNAs (miRNAs) in peritoneal exosomes that were isolated from 10 patients with epithelial ovarian cancer (EOC) with metastasis in the abdominal cavity and 10 participants without cancer (NC) were identified. These differentially expressed miRNAs that were revealed by next-generation sequencing were categorized by Gene Ontology enrichment and Kyoto Encyclopedia of Genes and Genomes pathway enrichment analysis of their target genes. Notably, two miRNAs that were associated with EOC-miR-149-3p and miR-222-5p-were identified. There were significant differences in expression of miR-149-3p and miR-222-5p between EOC and NC samples, and the effect of the expression level of the two miRNAs on the patient survival was identified using publicly available data from The Cancer Genome Atlas. There is an association between these two miRNAs and EOC, that was further verified by reverse transcription-quantitative polymerase chain reaction in peritoneal exosomes from 10 patients with EOC and NC participants. These results indicated that miR-149-3p and miR-222-5p might be novel biomarkers for evaluating the prognosis of patients with EOC and that these two miRNAs might have potential therapeutic values.
Identifiants
pubmed: 30655799
doi: 10.3892/ol.2018.9558
pii: OL-0-0-9558
pmc: PMC6313212
doi:
Types de publication
Journal Article
Langues
eng
Pagination
539-547Références
Cancer Res. 2005 Apr 15;65(8):3025-9
pubmed: 15833827
Int J Oncol. 2007 Aug;31(2):277-83
pubmed: 17611683
Cell Cycle. 2009 Jan 1;8(1):158-66
pubmed: 19158483
Cancer Lett. 2009 Jun 8;278(1):73-81
pubmed: 19188015
J Cell Mol Med. 2011 Jul;15(7):1593-602
pubmed: 20716115
Nat Med. 2011 Oct 30;17(11):1498-503
pubmed: 22037646
PLoS One. 2011;6(12):e28561
pubmed: 22194851
Annu Rev Immunol. 2012;30:295-312
pubmed: 22224773
Methods Mol Biol. 2012;863:293-302
pubmed: 22359301
J Cell Biol. 2013 Feb 18;200(4):373-83
pubmed: 23420871
Nat Genet. 2013 Oct;45(10):1134-40
pubmed: 24071852
Cancer Metastasis Rev. 2014 Mar;33(1):17-39
pubmed: 24357056
Lancet. 2014 Oct 11;384(9951):1376-88
pubmed: 24767708
Oncotarget. 2015 Feb 20;6(5):3280-91
pubmed: 25682864
Nat Rev Cancer. 2015 Jun;15(6):321-33
pubmed: 25998712
Nature. 2015 May 28;521(7553):489-94
pubmed: 26017449
Cancer Lett. 2015 Oct 10;367(1):26-33
pubmed: 26189430
Oncotarget. 2016 Nov 1;7(44):71960-71973
pubmed: 27713126
J Transl Med. 2016 Oct 19;14(1):297
pubmed: 27756426
Mol Cancer Res. 2017 Jan;15(1):78-92
pubmed: 27758876
Nat Rev Genet. 2016 Dec;17(12):719-732
pubmed: 27795564
Br J Pharmacol. 2017 Apr;174(7):553-568
pubmed: 28095588
Nat Commun. 2017 Mar 06;8:14470
pubmed: 28262727
Surg Oncol. 2017 Mar;26(1):46-52
pubmed: 28317584
Int J Oncol. 2017 May;50(5):1461-1476
pubmed: 28393213
Mol Cancer. 2017 May 15;16(1):92
pubmed: 28506269
J Cell Physiol. 2019 Apr;234(4):3180-3191
pubmed: 28628227
J Cell Physiol. 2018 May;233(5):3846-3854
pubmed: 28703277
Int J Mol Sci. 2017 Sep 13;18(9):null
pubmed: 28902136